Patient deaths trigger discontinuation of Ph 1 trial from SGR-2921 Program in R/R AML and HR-MDS patients
“Patient safety is our first priority, and in light of two treatment-related deaths in the Phase 1 dose-escalation study, we have made the decision to discontinue further development of SGR-2921. While disappointing given the early clinical activity observed, we believe this is the right decision for patients,” stated Margaret Dugan, M.D., chief medical officer at Schrödinger. “We had hoped to advance this investigational agent for acute myeloid leukemia as relapse rates are high, the disease progresses rapidly and there are limited therapies available. We are very grateful to the investigators, patients and families who have participated in this clinical study.”
Share:
More News
“The designation reinforces the significant unmet need for effective treatment options for patients with advanced breast cancer,” said Charles Baum, M.D., Ph.D., Chief Executive Officer of Terremoto Biosciences. “We are committed to advancing highly selective therapies designed to expand treatment options for patients with difficult to treat cancers.”
“Up to five U.S. clinical sites are planned for THIO-101 Parts C and D this year, and we expect to activate a second U.S. site in the coming weeks,” said Vlad Vitoc, M.D., Founder and Chief Executive Officer of MAIA. “To date, data has shown overall survival (OS) beyond two
Dr. Jason Zhu, Executive Director and Chief Executive Officer of Henlius, said: “The positive CHMP opinion for the sqNSCLC indication marks another important milestone in serplulimab’s regulatory journey in Europe and brings the product one step closer to achieving comprehensive coverage of first-line lung cancer treatment indications in the EU.